What is HC Wainwright’s Estimate for BOLT Q3 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Bolt Biotherapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will earn ($0.33) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million.

Separately, Stifel Nicolaus dropped their target price on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Price Performance

BOLT opened at $0.43 on Thursday. Bolt Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.56. The firm has a 50-day moving average of $0.47 and a 200 day moving average of $0.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The firm has a market cap of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. FMR LLC increased its holdings in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after acquiring an additional 28,773 shares during the last quarter. Millennium Management LLC bought a new position in Bolt Biotherapeutics during the fourth quarter worth about $25,000. Citadel Advisors LLC bought a new position in Bolt Biotherapeutics during the fourth quarter worth about $42,000. Squarepoint Ops LLC purchased a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $26,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at approximately $27,000. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.